



## **Pixium Vision makes available its 2017 Registration Document**

**Paris, France. 26 March 2018** – Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced that its 2017 Registration Document has been filed with the Autorité des Marchés Financiers (AMF).

The Registration Document includes notably the annual financial report, the report by the Board of Directors on corporate governance as well as the reports of the statutory auditors.

The 2017 Registration Document is available on the company's website ([www.pixium-vision.com](http://www.pixium-vision.com)) and on the AMF website ([www.amf-france.org](http://www.amf-france.org)). The Registration Document is also available at the registered office of the company: 74 rue du Faubourg Saint Antoine, 75012 Paris.

### **Contacts**

**Pixium Vision**

Didier Laurens, CFO

[investors@pixium-vision.com](mailto:investors@pixium-vision.com)

+33 1 76 21 47 68



@PixiumVision

## ABOUT PIXIUM VISION

Pixium Vision's mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision is now conducting a clinical study<sup>1</sup> in Human with PRIMA, its new generation sub-retinal miniaturized photovoltaic wireless implant system, for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Stanford University in California, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" par Bpifrance.

For more information, please visit:  [www.pixium-vision.com](http://www.pixium-vision.com);

And follow us on:  @PixiumVision;  [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

**Linked**  [www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)

**PIX**  
**LISTED**  
**EURONEXT**



Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

### Disclaimer:

*This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.*

*Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.*

*For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF on March 26, 2018 which can be found on the websites of the AMF ([www.amf-france.org](http://www.amf-france.org)) and of Pixium Vision ([www.pixium-vision.com](http://www.pixium-vision.com)).*

*IRIS® is a trademark of Pixium-Vision SA*